Daily as of 3 Nov 16:00 ET
- Price
- above both $128.62 vs 50 $114.52 / 200 $83.94
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 6 Jul 2026 · projected 20 bars out
HALO | Halozyme TherapeuticsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history
$128.62
-$0.33 (-0.26%)
Halozyme Therapeutics (HALO) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2018.
The 50 SMA has sat above the 200 on the daily since Jul 2026, with no cross projected inside the 30 bars Cruxta tracks. Price sits above the 50 and the 200 on the daily, the weekly and the 4-hour.
Timeframe summary
Weekly as of 30 Oct 16:00 ET
- Price
- above both $130.91 vs 50 $81.06 / 200 $57.14
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross week of 19 Aug 2024 · projected 27 bars out
4-hour as of 3 Nov 16:00 ET
- Price
- above both $128.62 vs 50 $119.50 / 200 $99.09
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 12 Jun 2026 bar 1 · projected 16 bars out · tested 5 bars
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| 6 Jul 2026 | 🟨Golden moderate | daily | 20 bars out | Not tested |
| 12 Jun 2026 | 🟨Golden | 4-hour | 16 bars out | 5 bar cross test |
| 22 Apr 2026 | 💀Death moderate | daily | 29 bars out | 1 bar cross test |
| 19 Mar 2026 | 💀Death | 4-hour | 26 bars out | Not tested |
| 22 Jan 2026 | 🟨Golden | 4-hour | 26 bars out | 7 bar cross test |
About HALO
ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$217M
4-hour coverageYes, since Oct 2025
History on recordSince 2018
SectorHealthcare
Cap bandlarge